Browsing by Author "Saber O."
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
Item Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma(Future Medicine Ltd., 2018) Ali M.A.; Matboli M.; El-Khazragy N.; Saber O.; El-Nakeep S.; Abdelzaher H.M.; Shafei A.E.-S.; Mostafa R.; Department of Biomedical Research; Armed Forces College of Medicine (AFCM); Cairo; 11774; Egypt; Department of Medical Biochemistry and Molecular Biology; Ain Shams Faculty of Medicine Research Center (Masri)11778; Egypt; Department of Clinical Pathology; Oncology Diagnostic Unit; Faculty of Medicine; Ain Shams University; Cairo; 11778; Egypt; Armed Forces College of Medicine (AFCM); Cairo; 11774; Egypt; Hepatology and Gastroenterology Unit; Internal Medicine Department; Faculty of Medicine; Ain Shams University; Cairo; 11778; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; Cairo; 12585; EgyptAim: We aimed to examine the statistical association between serum expression of miRNA 661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico data analysis followed by clinical validation. Patients & methods: Quantitative reverse-transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B mRNA in the sera of HCC patients versus control. Results: The expression of miR-661 and ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The survival analysis showed that ATG-4B mRNA was an independent prognostic factor. Conclusion: Our data are the first report of its kind regarding the considerable clinical significance of miR-661 and ATG-4B mRNA in HCC patients. � 2018 2018 Future Medicine Ltd.